Pomerantz recently achieved a $47 million settlement on behalf of defrauded investors in a securities litigation against the American biotechnology company Novavax. The suit revolves around allegedly misleading statements made regarding the development and imminent approval of the company’s Covid-19 vaccine candidate.
Read MorePomerantz was named Co-Lead Counsel in a shareholder suit against Bausch Health Companies, Inc. The suit alleges that Bausch misled investors about the company’s financial standing when Bausch planned to spin off its subsidiary Bausch + Lomb Corporation (B+L), an eye health company.
Read MoreLast week, Pomerantz moved the court to approve a $97 million settlement in a securities fraud class action against the pharmaceutical company Perrigo Co. plc. The proposed settlement follows a multi-year litigation that included 40 depositions and the review of over half a million documents. Managing Partner Jeremy Lieberman expressed his satisfaction at the result: “We are very proud of our team’s hard-fought accomplishment in bringing this case to a successful resolution after nearly eight years of litigation through a ruling on summary judgment.”
Read MorePomerantz has been named co-lead counsel in a securities class action against Canopy Growth Corporation concerning alleged material misstatements and omissions related to the company’s financial performance and internal controls.
Read MorePomerantz is proud to announce that Partner Emma Gilmore has been named the 2024 Plaintiff Litigator of the Year by Benchmark Litigation. “I am honored to receive the Plaintiff Litigator of the Year award from Benchmark Litigation,” said Emma. “I also wish to congratulate my fellow nominees who represented a diverse and talented group of litigators.” The award was announced on March 13th at an event in New York City.
Read MorePomerantz was recently named Co-Lead Counsel in a shareholder suit against PacWest Bancorp. The suit alleges that PacWest misled investors about the company’s financial situation and the effect that increases in interest rates would have on its liquidity.
Read MorePomerantz recently achieved a $3 million settlement with the agricultural biotechnology company 22nd Century Group, Inc. The investor suit alleged, among other things, that the company concealed an SEC investigation into its accounting controls.
Read MorePomerantz was recently appointed co-lead counsel in a securities class action against the pharmaceutical company Apellis. The suit alleges that the company misled investors about the safety of one of its treatments for an eye condition that can lead to blindness.
Read MorePomerantz recently resolved a shareholder litigation against Teva Pharmaceuticals Ltd., in which Pomerantz represented 22 Israeli institutional investors who had opted out of a previous securities class action. The case concerned an alleged price-fixing scheme as well as Teva’s role in the devastating U.S. opioid crisis.
Read MoreOn January 4, United States Magistrate Judge James R. Cho of the United States District Court for the Eastern District of New York named Pomerantz Lead Counsel in a securities class action against Uruguayan fintech company DLocal. The case alleges that DLocal made misleading statements about its compliance with Argentine financial regulations.
Read MorePomerantz continues to rack up accolades, with several attorneys featuring prominently in the 2024 edition of the Benchmark Litigation guide.
Read MorePomerantz was recently appointed Lead Counsel in a securities class action against medical and commercial manufacturing conglomerate Danaher Corporation. The suit alleges that Danaher misled investors about the company’s financial prospects following the growth it experienced during the COVID-19 pandemic.
Read More